Gastrointestinal Cancer | Specialty

The Future of Personalized Therapy in Advanced HCC

September 10th 2019

Combinations May Be the Future in HCC

September 10th 2019

Optimal Management of Early-Stage HCC

September 10th 2019

Pancreatic NETs Subtypes Could Signal Risk of Recurrence

September 9th 2019

Two distinct subtypes of nonfunctional pancreatic neuroendocrine tumors could help prognosticate risk of recurrence following surgery.

Dr. Fakih on Future Directions in CRC

September 6th 2019

Marwan Fakih, MD, professor, Department of Medical Oncology and Therapeutics Research, associate director for Clinical Investigations, Comprehensive Cancer Center, medical director, Judy and Bernard Briskin Center for Clinical Research, co-director, Gastrointestinal Cancer Program, and section head, Gastrointestinal Medical Oncology, City of Hope, discusses future directions in metastatic colorectal cancer (mCRC).

Shorter Adjuvant Oxaliplatin-Based Therapy Less Effective in High-Risk Stage II CRC

September 6th 2019

Three months of adjuvant oxaliplatin-based therapy in patients with high-risk, stage II colorectal cancer was found to be inferior to 6 months of treatment.

Dr. Manji on Treatment for Right-Sided Tumors in CRC

September 4th 2019

Gulam A. Manji, MD, PhD, discusses the difference between right- and left-sided tumors in colorectal cancer and the appropriate treatment for right-sided tumors based on a subgroup analysis.

Dr. Davis on Immunotherapy in HER2-Positive Gastric/GEJ Cancer

September 4th 2019

S. Lindsey Davis, MD, an assistant professor of medicine and gastrointestinal medical oncologist at the University of Colorado Cancer Center, discusses an investigational immunotherapy combination being explored in patients with HER2-positive gastric and gastroesophageal junction (GEJ) cancer.

Dr. Pinato on Molecular Characterization of Tumor Microenvironment in NETs

September 3rd 2019

David J. Pinato, MD, PhD, clinical senior lecturer in medical oncology, clinician scientist, consultant medical oncologist, Department of Surgery and Cancer, Imperial College London, discusses the molecular makeup of the tumor microenvironment in neuroendocrine malignancies.

Dr. Lenz on the Safety Profile in CheckMate-142 Trial in CRC

August 28th 2019

Heinz-Josef Lenz, MD, FACP, discusses the safety profile of nivolumab plus ipilimumab in the phase II CheckMate-142 trial for treatment-naïve patients with microsatellite instability–high/mismatch repair deficient colorectal cancer.

TAS-102 Nabs Japanese Approval for Gastric Cancer

August 23rd 2019

The Japanese Ministry of Health, Labour and Welfare has approved TAS-102 (trifluridine/tipiracil; Lonsurf) for the treatment of patients with unresectable advanced or recurrent gastric cancer that has progressed after chemotherapy.

Frontline Nivolumab/Ipilimumab Combo Shows Robust Activity in MSI-H/dMMR mCRC

August 23rd 2019

The frontline combination of nivolumab (Opdivo) and ipilimumab (Yervoy) showed a robust and durable clinical benefit in patients with metastatic colorectal cancer.

Dr. Philip on Adverse Events With Lutathera in NETs

August 23rd 2019

Philip A. Philip, MD, PhD, FRCP, professor of medicine, Wayne State University School of Medicine, clinical professor of oncology at Barbara Ann Karmanos Cancer Institute, discusses adverse events (AEs) associated with Lutathera (lutetium Lu 177 dotatate) in neuroendocrine tumors (NETs).

Regorafenib/Nivolumab Combo Elicits Responses in CRC and Gastric Cancer

August 21st 2019

Shota Fukuoka, MD, PhD, discusses the results of the study evaluating regorafenib and nivolumab in patients with previously treated gastric and colorectal cancers.

Dr. Lee on Data Regarding HIPEC in mCRC

August 20th 2019

Byrne Lee, MD, chief, Upper GI and Mixed Tumor Surgery Service, associate clinical professor of surgical oncology, Department of Surgery, and surgical oncologist, City of Hope, discusses data regarding the use of hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with metastatic colorectal cancer (mCRC).

Dr. Davis on the Role of Ramucirumab in Gastric/GEJ Cancer

August 20th 2019

S. Lindsey Davis, MD, an assistant professor of medicine and gastrointestinal medical oncologist at the University of Colorado Cancer Center, discusses the role of ramucirumab (Cyramza) in the treatment of patients with gastric/gastroesophageal junction (GEJ) adenocarcinoma.

ctDNA Testing Now Valuable Tool in CRC, Next Steps Underway

August 20th 2019

Pashtoon M. Kasi, MBBS, MD, MS, discusses the use of ctDNA testing throughout treatment for patients with colorectal cancer and ongoing research on liquid biopsies.

Dr. Manji on Treatment for BRAF-Mutant CRC

August 16th 2019

Gulam A. Manji, MD, PhD, discusses clinical trials for patients with colorectal cancer harboring BRAF or other molecular abnormalities.

Key Takeaway 6: Role of Immunotherapy in R/R mHCC

August 15th 2019

Key Takeaway 5: High AFP is a Biomarker for Ramucirumab

August 15th 2019